Indian pharmaceutical market has posted a growth of 8.3 per cent for the month of April 2017 to Rs.9,474 crore as against 5.5 per cent registered in the corresponding period of last year. According to AIOCD Pharmasofttech AWACS report, major segments like Anti-diabetic and Derma have grown by double digit and Anti Infectives segment has not degrown for the month. Cardio segment has posted single digit growth for the month, CNS also growing by single digit. The April quarter saw a volume growth of 3.4 per cent & price growth at 1.4 per cent which has been consistently falling down.
FDC related market show a degrowth of -18.4 per cent while the Non FDC market is growing at 8.9 per cent. Volumes are pulling down the growth for the FDCs. Indian companies showed a degrowth of negative 7.8 per cent while MNC showed a degrowth of -39.2 per cent in the FDC segment in April 2017.
Sun Pharma has the highest growth at 11.3 per cent followed by Mankind at 11.2 per cent and Lupin at 10.8 per cent. Glaxo is showing signs of recovery by posting monthly growth of 10.1 per cent for the month of April. 27 corporate have crossed the growth of IPM for the month. Amongst the top 50 corporate Wockhardt has the highest growth of 24.3 per cent followed by Micro Labs at 19.8 per cent and Himalaya at 19.3 per cent. 24 corporate showed growths more than 10 per cent amongst the top 50. Abbott HC grew at 1.1 per cent whereas Abbott India grew at 11.1 per cent for the month of Apr-17. Zuventus grows at 14.1 per cent, Emcure at 18.6 per cent, Micro Labs is growing 20.4 per cent.
Indian companies grew by 9.1 per cent for the month while the MNC grew by 5.2 per cent. Amongst the top 50 in MNCs, Boehringer Ingelheim grew at 20.2 per cent followed by AstraZeneca growing at 12.1 per cent and Janssen which grew at 11.4 per cent.
The NLEM 2013 containing molecules market grew at negative 5.3 per cent whereas the non NLEM market grew by 10.4 per cnet resulting in an overall growth of 8.3 per cent for the month of April 2017.NLEM & Non – NLEM Category showed unit growth of 3.4 per cent and 1.4 per cent respectively.
From therapy perspective, 10 therapies have outgrown the IPM growth for the month of April 2017. Respiratory market grew at 5.3 per cent, Gastro Intestinal market grew at 7.6 per cent, Pain & Analgesics market grew at 7.5 per cent and Anti Infectives degrowth has been stemmed as it showed a small growth of 0.6 per cent. Anti-diabetic market grows at 17.8 per cnet & Cardiac at 8.7 per cent, Neuro/ CNS at 5.4 per cent in Chronic Business. Anti-Malarials degrew at -16.6 per cent & VMS Market grew at 5.1 per cent. Derma is growing faster than even Cardio segment at 13.9 per cent for the month of April -17
From regional perspective 14 regions have outgrown the IPM growth for the month. Jharkhand market grew the highest at 21.6 per cent followed by North Karnataka at 20.47 per cent & South Rajasthan at 20.36 per cent. Five regions had negative growth in April-17.